SEC Form 4 · accession 0001209191-17-059944
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Brett Primiano
Officer — SVP, OPS, BUS DEV, GC & SEC
Period of report
Nov 7, 2017
Accepted (ET)
Nov 9, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 7, 2017 | S | 4,958 | $11.2455 | D | 21,423 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- F2The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 6, 2017 and November 7, 2017 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.